The DOI matches its Crossref record.
Combination therapy of in vitro‐expanded natural killer T cells and α‐galactosylceramide‐pulsed antigen‐presenting cells in patients with recurrent head and neck carcinoma
Open accessAbstract
The aim of this clinical trial was to investigate the feasibility of intra‐arterial infusion of in vitro‐expanded Vα24 natural killer T (NKT) cells combined with submucosal injection of α‐galactosylceramide (KRN7000; αGalCer)‐pulsed antigen‐presenting cells (APC). A phase I clinical study was carried out in patients with head and neck squamous cell carcinoma (HNSCC). Patients with locally recurrent HNSCC refractory to standard therapy were eligible. Eight patients received super‐selective transcatheter intra‐arterial infusion of activated Vα24 NKT cells into tumor‐feeding arteries and nasal submucosal injections of αGalCer‐pulsed APC twice with a 1‐week interval. Vα24 NKT cell‐specific immune responses, safety, and antitumor effects were evaluated. The number of Vα24 NKT cells and interferon‐γ‐producing cells in peripheral blood mononuclear cells increased in seven out of eight patients enrolled. Grade 3 toxicity with a pharyngocutaneous fistula related to local tumor reduction was observed in one patient and mild adverse events with grade 1–2 symptoms occurred in seven patients. Regarding the clinical responses, three cases exhibited a partial but significant response, four were classified as stable disease, and one patient continued to develop progressive disease. The use of the intra‐arterial infusion of activated Vα24 NKT cells and the submucosal injection of αGalCer‐pulsed APC has been shown to induce significant antitumor immunity and had beneficial clinical effects in the management of advanced HNSCC. The use of such therapeutic modalities may be helpful in the management of tumors and therefore needs to be explored in further detail. The clinical trial registration number was UMIN000000722. (Cancer Sci 2009; 100: 1092–1098)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Targeting natural killer cells and natural killer T cells in cancer
Vivier, E., Ugolini, S., Blaise, D., Chabannon, C., & Brossay, L. (2012) · Nature Reviews Immunology · doi:10.1038/nri3174 · Cited by 850
Recognition of CD1d-restricted antigens by natural killer T cells
Rossjohn, J., Pellicci, D. G., Patel, O., Gapin, L., & Godfrey, D. I. (2012) · Nature Reviews Immunology · doi:10.1038/nri3328 · Cited by 460
Presumed guilty: natural killer T cell defects and human disease
Berzins, S. P., Smyth, M. J., & Baxter, A. G. (2011) · Nature Reviews Immunology · doi:10.1038/nri2904 · Cited by 365
Canning, M., Guo, G., Yu, M., Myint, C., Groves, M. W., Byrd, J. K., & Cui, Y. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00052 · Cited by 331
Unconventional T Cell Targets for Cancer Immunotherapy
Godfrey, D. I., Le Nours, J., Andrews, D. M., Uldrich, A. P., & Rossjohn, J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.009 · Cited by 314
Metadata
- Authors
- Kunii, N., Horiguchi, S., Motohashi, S., Yamamoto, H., Ueno, N., Yamamoto, S., Sakurai, D., Taniguchi, M., Nakayama, T., & Okamoto, Y.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2009-05-20
- Volume
- 100
- Issue
- 6
- Pages
- 1092-1098
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W2034857439
- Cited by
- 184
- References
- 0
- FWCI
- 5.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combination therapy of in vitro‐expanded natural killer T cells and α‐galactosylceramide‐pulsed antigen‐presenting cells in patients with recurrent head and neck carcinoma. https://app.cochat.ai/papers/10.1111/j.1349-7006.2009.01135.x
- The paper
- Kunii, N., Horiguchi, S., Motohashi, S., Yamamoto, H., Ueno, N., Yamamoto, S., Sakurai, D., Taniguchi, M., Nakayama, T., & Okamoto, Y. (2009). Combination therapy of in vitro‐expanded natural killer T cells and α‐galactosylceramide‐pulsed antigen‐presenting cells in patients with recurrent head and neck carcinoma. Cancer Science. https://doi.org/10.1111/j.1349-7006.2009.01135.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.